<DOC>
	<DOCNO>NCT00224783</DOCNO>
	<brief_summary>The primary objective study investigate safety tolerability CAIV-T liquid formulation healthy Japanese male adult .</brief_summary>
	<brief_title>Phase I Trial Evaluating Safety Tolerability CAIV-T Healthy Japanese Male Adults</brief_title>
	<detailed_description>The primary objective study investigate safety tolerability CAIV-T liquid formulation healthy Japanese male adult evaluate incidence influenza-like symptom , type , incidence , severity adverse event .</detailed_description>
	<mesh_term>Potassium phosphate</mesh_term>
	<criteria>Age 20 year old 45 year old ( time consent ) Persons judge suitable principal investigator investigator result prior history , physical examination clinical finding . Persons ability understand consent write consent obtain prior start screening . Persons able participate trial 1 month inoculation trial vaccine completion trial . Persons able contact ( phone , hospital visit house visit ) trial staff time test 28 day inoculation trial vaccine . Persons judge impossible difficult contact request hospital visit carry clinical evaluation test trial term . Persons prior history suspect immunological disease , receive administration systemic corticosteroid immunosuppressant cytotoxic drug ( e.g. , methotrexate , etc . ) Persons blood formulation immunoglobulin , etc. , administer plan period one month inoculation trial vaccine completion trial . Persons live person nonfunctional suppress immune system ( use immunosuppressant , etc . ) , household . Persons prior history hypersensitivity chicken egg chicken egg protein component trial vaccine ( sucrose , phosphoric acid , glutamate , arginine acidhydrolyzed pig gelatin ) . Persons inoculate live virus vaccine within 1 month screening . Persons plan administration another trial vaccine drug period one month screen completion trial Person influenza treatment drug ( commercially available drug trial vaccine : example , Oseltamivir , Zanamivir , Amantadine , etc . ) , administer within one month screening . Incidentally , prophylactic administration influenza viral drug permit . Persons inoculate influenza vaccine within 6 month screen plan inoculated influenza vaccine term present trial . Persons blood draw quantity ( include blood donation ) 400 mL within 3 month 200 mL within 1 month screening . Persons history febrile disorder ( oral cavity temperature ³ 38.0°C ) acute disorder within 36 hour trial vaccine inoculation . Persons upper respiratory tract disorder whose family member disorder within 72 hour trial vaccine inoculation . Persons treat antibiotic within 72 hour trial vaccine inoculation . Persons acute asthmatic symptom . Persons judge pathology prevent evaluation trial effect principal investigator ( investigator ) .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>